BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7835782)

  • 1. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines.
    Jones J; Lagasse LD; Karlan BY
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):421-6. PubMed ID: 7835782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
    Read LD; Keith D; Slamon DJ; Katzenellenbogen BS
    Cancer Res; 1990 Jul; 50(13):3947-51. PubMed ID: 1972345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
    Runnebaum IB; Brüning A
    Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
    Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
    Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable suppression of HER-2 gene expression using siRNA increases the lysis of human ovarian carcinoma cells mediated by NK-92 cell line.
    Zhou Y; Cheng Z; Zhu H; Feng D; Zhao W; Ling B; Wei H; Tian Z
    Oncol Rep; 2008 Dec; 20(6):1425-31. PubMed ID: 19020724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
    Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
    Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Lostumbo A; Mehta D; Setty S; Nunez R
    Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD; Karlan BY
    J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
    Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
    Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells.
    Mukherjee K; Syed V; Ho SM
    Oncogene; 2005 Jun; 24(27):4388-400. PubMed ID: 15806153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
    Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
    Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.